FDA Says Three Walmart.com Herpes-Symptom Products Are Unapproved Drugs, Sets 15-Business-Day Deadline

The FDA made public on Tuesday a warning letter to Walmart, dated Thursday, saying three products sold on walmart.com are unapproved new drugs because their labels claim to treat genital herpes or genital sores. A warning letter is the agency's formal notice of violations; it is not a fine, a recall or a sales ban.

What the letter says

The FDA addressed the letter to John Furner and named three products: "HClear for him," "Herstat GST" and "Terragen HG Formula." The agency said it bought all three on walmart.com in July 2026.

According to the letter, Walmart delivered the products into interstate commerce through Walmart Fulfillment Services, on behalf of third-party sellers. The letter quotes Walmart's own site describing that service: it will "pick, pack and ship the item to the customer on the seller's behalf."

The FDA cited label claims as evidence the products are sold as drugs. For HClear for him, they include "FAST-ACTING OUTBREAK SYMPTOM RELIEF ITCHING, TINGLING, PAIN & BURNING." Herstat GST is labeled "Genital Sore Treatment," and Terragen HG Formula claims "relief of swelling and pain associated with genital sores."

The letter says the FDA has not approved any over-the-counter product to treat, cure or prevent any sexually transmitted infection. It warns that people relying on such products may skip proper care, risking complications "such as infertility, sepsis, and death."

The homeopathic and monograph points

Terragen HG Formula is labeled homeopathic. The FDA said homeopathic drugs face the same approval requirements as other drugs.

HClear for him is also labeled homeopathic, but the letter says it falls outside the agency's homeopathic enforcement guidance because it lists "lemongrass 2X HPUS," which is not a listed active ingredient. The FDA added that even if it qualified, it would fall in a higher-risk category the agency intends to prioritize.

For Herstat GST, the letter says its genital-sore claims go beyond the uses allowed under the over-the-counter external analgesic monograph, so it cannot be sold legally without an approved application.

What Walmart must do

The letter gives Walmart 15 business days from receipt to reply in writing to FDAAdvisory@fda.hhs.gov, citing the reference number the FDA gives in the letter. The reply must lay out corrective steps, how recurrence will be prevented, and supporting documents.

The FDA said failure to address the violations may bring regulatory or legal action without further notice, including seizure and injunction. The letter does not itself impose any of those.

The letter is dated Thursday and was posted Tuesday, five days later. In Tuesday pre-market trading, Walmart shares were down 0.30% to $104.76 (market data).

Walmart's written response is due within 15 business days of receipt, and the FDA says it will consider any evidence the products comply.

Sources

• Warning letter — Walmart, Inc. (MARCS-CMS 736557) — U.S. Food and Drug Administration